Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

Phase 1

Completed

Conditions: Bladder Cancer

Interventions: Drug: Avelumab
Biological: BCG

Registration Number: NCT03892642

Lead Sponsor: University of Oklahoma

Brief Summary: The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.

Detailed Description: There will be exams, tests and procedures to see if the patient is eligible for the study. Some are part of regular cancer care and others are part of the study. Subjects will also need to complete a research questionnaire at certain points in the study.

Subjects will receive treatment of avelumab and intravesical BCG until unacceptable toxicity or tumor progression.

Study participation is up to three years.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 18

Inclusion Criteria

Histologically or cytologically documented Non-muscle Invasive Bladder Cancer (NMIBC)
Patient with BCG-treated but unresponsive NMIBC (persistent or recurrent defined as tumor lesion present after prior response).
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2.
Patients who are able to understand and sign the informed consent form.
Age ≥ 18 years old
Ability to comply with protocol
Life expectancy >/=12 weeks
Adequate hematologic and end-organ function per protocol
For women of childbearing potential: Negative serum or urine pregnancy test at screening.
For both male and female subjects: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 30 days after the last dose of study drug.

Exclusion Criteria

Evidence of locally advanced or metastatic bladder cancer (including current disease involving renal pelvis, ureter, or prostatic urethra).
Evidence of muscle-invasive bladder cancer
Evidence of extravesical bladder cancer
Active central nervous system (CNS) metastases.
Prior treatment with PD-L1 or PD-1 inhibitor.
Prior radiation to bladder
Known additional malignancy that required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin.
Patient is considered a poor medical risk that would interfere with cooperation with the requirements of the study.
Patient has a condition or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
Patient has not recovered (i.e, to ≤Grade 1 or to baseline) from previous intravesical BCG or other anti-cancer therapy induced AEs.
Treatment with any approved anti-cancer therapy, including chemotherapy (systemic or intravesical), radiation therapy, or hormonal therapy within 3 weeks prior to the first dose of study treatment
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 4 weeks prior to the first dose of study treatment
Pregnant or lactating, or intending to become pregnant during the study

a. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to the first dose of study treatment.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
Allergy or hypersensitivity to components of the avelumab formulation
History of autoimmune disease defined per protocol
Prior allogeneic stem cell or solid organ transplantation
Current use of immunosuppressive medication defined per protocol
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan

a. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Positive test for HIV
Active hepatitis B (positive hepatitis B surface antigen [HBsAg] test at screening);

a. Patients with past or resolved hepatitis B (HBV) infection (positive anti-hepatitis B core antigen [anti-HBc] antibody test) are eligible. HBV DNA must be obtained in these patients prior to the first dose of study treatment.
Active hepatitis C

a. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction assay is negative for HCV RNA.
Active infection requiring systemic therapy
Severe infections within 4 weeks prior to the first dose of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
Significant cardiovascular disease, such as cerebral vascular accident/stroke (< 6 months prior to enrollment), New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina
Administration of a live/attenuated vaccine within 4 weeks prior to the first dose of study treatment, within 5 months following the administration of the last dose of study drug, or anticipation that such a live/attenuated vaccine will be required during the study
Other severe acute or chronic medical conditions defined per protocol

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BCG + Avelumab	BCG	Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
BCG + Avelumab	Avelumab	Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.

Primary Outcome Measures

Name	Time	Method
Proportion of Patients Receiving Complete Induction Course	8 weeks	Proportion of patients receiving complete induction course, defined as freedom from DLT preventing completion of at least 5 of 6 treatments of BCG + avelumab

Secondary Outcome Measures

Name	Time	Method
Proportion of Patients With Recurrence Free Survival	12 months	defined as proportion of patients who are alive and free of persistent or recurrent NMIBC based on cystoscopy, cytology and/or biopsy
Proportion of Patients With Progression-free Survival	12 months	defined by time from day of first treatment to first progression to higher grade or stage, including muscle-invasive disease or death from any cause
Proportion of Patients Receiving Complete Induction Course	5 weeks	completion of at least 2 of 3 treatments within each 5 week period
Percent of Patients With Complete Response	3 months	based on negative cystoscopy and urine cytology. A negative biopsy at 6 months will provide evidence of complete response.
Proportion of Patients With Complete Response	6 months	based on negative cystoscopy and urine cytology. A negative biopsy at 6 months will provide evidence of complete response.
Percent of Patients With Recurrence Free Survival	6 months	defined as percent of patients who are alive and free of persistent or recurrent NMIBC based on cystoscopy, cytology and/or biopsy.